The largest program at SMRI is for the identification of medications that will improve the treatment of schizophrenia and bipolar disorder. Although medications have been available since the 1960s, they have proven to be only partially effective. Many individuals affected with these diseases continue to have symptoms even when taking available medications, while others find it difficult to take medications because of side effects.
The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. At any given time, SMRI is supporting 50-60 treatment trials, the majority of which are generic and/or off-label medications.
2017 Request for Applications:
SMRI is soliciting applications again this year for treatment trials of biological interventions which may be useful for improving the symptoms of individuals with schizophrenia or bipolar disorder. We currently have 54 trials ongoing, and expect to fund 5 to 7 more this year. The deadline for applications is March 1st, 2017.
SMRI is most interested in supporting research on the efficacy of drugs for which pharmaceutical companies are unlikely to be interested because the drugs lack commercial potential. Such drugs include those which have lost patent protection, off-label indications, repurposing, etc. SMRI aims to support clinical trials testing the efficacy of compounds or biological interventions. Although studies can include a psychosocial component, studies that have a psychosocial intervention as the primary focus will not be considered, nor will analyses of existing data, or trials of drugs focused on alleviating side effects of existing medications. Applications should include information regarding whether the proposed compound crosses the blood brain barrier, with supporting data. If the compound does not cross the blood brain barrier, explanation will be needed as to why the compound could be helpful for treating schizophrenia or bipolar disorder. SMRI is particularly interested in proposals testing the efficacy of anti-inflammatory drugs. Regarding monoclonal antibody trials, we are currently funding 4 such trials and will not fund additional trials this year.
In addition to SMRI’s program for reprograming drugs for schizophrenia and bipolar disorder, there is another interesting program in the UK, called the ECNP Medicine Chest Initiative, consisting of a list of drugs which were being developed by drug companies but which have been put aside for one reason or another. A description of this program and the list of the drugs available for academic testing is at https://www.ecnp.eu/projects-initiatives/ECNP-medicines-chest.aspx. Such drugs could be included in an application to SMRI.
The recent death of Mr. Stanley has meant that our funds and time are limited. Therefore we can only fund studies that can be finished and have results in no more than 5 years after funding. If you cannot guarantee that your study will be finished and results analysed within 5 years of funding, please do not submit a proposal to us. Progress of funded studies will be monitored in an ongoing fashion, and if it becomes clear that a study will not be completed on time, it will be terminated.
Drugs that are currently being investigated by SMRI, and those that have been funded in the past are on the List of Awarded Treatment Trials.
Do you have an ongoing trial with SMRI? Please submit your quarterly report here. Please note that quarterly reports are due April 15, July 15 and October 15
Do You Need to Access Past Applications and Quarterly Reports from our Old Website?
Please login here to review past submissions. SMRI does not retain usernames and passwords from the old website.